For IBS patients interested in exploring GLP-1 therapy, the Precision Peptide Genetic Test ($99 add-on after first month of treatment) provides personalized insights into whether your genetic profile suggests a favorable response to semaglutide injections or whether an alternative approach might be more appropriate
This includes beneficiaries who initiated therapy prior to enrolling in Medicare Part D and/or prior to the July 1, 2026 launch of the Medicare GLP-1 Bridge
Reaching that target matters enormously because it significantly reduces the risk of diabetes-related complications including neuropathy, retinopathy, and kidney disease
subsequent evaluations may provide more information
This pricing structure removes barriers to optimal dosing and ensures you reach your therapeutic level without financial strain
Delivered in a filler-free pullulan capsule, with no microcrystalline cellulose, magnesium stearate, or titanium dioxide